ArticleFrontiers in cell and developmental biology2026
An entosis-informed prognostic index for survival stratification and molecular characterization in lung adenocarcinoma.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Entosis is an actomyosin-dependent cell-in-cell process that may culminate in lysosome-mediated entotic cell death and is implicated in tumor evolution. Its clinical relevance in lung adenocarcinoma (LUAD) remains unclear. Methods: To construct an Entosis-related Prognostic Prediction Index (EPPI), this study integrated TCGA-LUAD transcriptomic, clinical, and somatic mutation data. Three independent GEO cohorts provided external validation. The initial candidate gene set covered components driving cell-in-cell formation and the intracellular degradation of internalized cells. For subgroup comparison, the analytical approach incorporated survival analysis, functional enrichment, tumor microenvironment profiling, mutation analysis, immunotherapy assessment, and drug-sensitivity prediction. Tissue and cellular distributions of the EPPI genes were mapped using spatial transcriptomics and single-cell RNA sequencing. Molecular docking assessed predicted drug-target interactions. Finally, Results: Comprising RND3, RAC1, KRAS, CTNNA1, AURKA, and ACTB, the final EPPI consistently stratified overall survival across all cohorts and showed moderate prognostic discrimination. The high-EPPI group had greater tumor purity and mutational burden, with enhanced cell-cycle, DNA-repair, epithelial-mesenchymal transition, and NF-κB programs, whereas the low-EPPI group showed greater immune and stromal infiltration. TIDE and immunophenoscores also differed between subgroups. Drug-response models predicted greater sensitivity to cisplatin and paclitaxel in the high-EPPI group and to several targeted agents in the low-EPPI group. Molecular docking predicted RAC1-EHT-1864 and AURKA-alisertib interactions. Spatial and single-cell analyses showed heterogeneous EPPI-gene expression, with ACTB and RAC1 broadly distributed and AURKA restricted to selected populations. RAC1 depletion suppressed LUAD-cell proliferation, DNA synthesis, migration, and invasion. Conclusion: The EPPI is an entosis-informed prognostic index for survival stratification in LUAD. Based on this index, patients can be separated into subgroups with distinct proliferative features, genomic alterations, tissue compositions, and predicted drug sensitivities. These findings associate entosis-related molecular features with distinct cellular and clinical characteristics of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.